Top Markets
#1 NKN NKN +163.44%
#2 Bluwhale Bluwhale +34.86%
#3 Codatta Codatta +29.93%
#4 SAFEcoin SAFEcoin +28.49%
#5 Saakuru Saakuru +24.27%
#6 StakeStone StakeStone +19.47%
#7 Yooldo Games Yooldo Games +16.45%
#8 Particle Network Particle Network +16.23%
#9 TronBank TronBank +13.65%
#10 Arcblock Arcblock +13.56%
Coin of the day
NKN NKN
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Classement en actions #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Prix de l'action
$0.15
Capitalisation boursière
$4.96M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
CA
Échange Intellipharmaceutics International Inc. (IPCIF)

Catégorie

Healthcare
Nombre d'actions en circulation pour Intellipharmaceutics International Inc. (IPCIF)
Nombre d'actions en circulation au August 2023: 33.09M
Selon les derniers rapports financiers et le cours de l'action de Intellipharmaceutics International Inc., le nombre actuel d'actions en circulation est de 33.09M. À la fin de November 2021, l'entreprise avait 29.43M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Intellipharmaceutics International Inc. (IPCIF) de 1999 à 2026
Actions en circulation à la fin de chaque année
Année Actions en circulation Changez
2026 (TTM) 33.09M 0.00%
2022 33.09M 12.45%
2021 29.43M 24.90%
2020 23.56M 9.18%
2019 21.58M 353.15%
2018 4.76M 53.55%
2017 3.10M 16.16%
2016 2.67M 12.34%
2015 2.38M 3.11%
2014 2.31M 17.18%
2013 1.97M 13.98%
2012 1.73M 15.10%
2011 1.50M 37.47%
2010 1.09M -51.30%
2008 2.24M 13.63%
2007 1.97M 124.16%
2006 879.29K 10.85%
2005 793.22K 15.41%
2004 687.29K 11.69%
2003 615.38K 27.29%
2002 483.46K 7.69%
2001 448.93K 2.77%
2000 436.82K 49.40%
1999 292.38K 0.00%
Actions en circulation pour des entreprises similaires ou concurrentes
Entreprise Actions en circulation Différence Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 13,340.60%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 667.24%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M 210.95%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M 474.14%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 61.42M 85.60%
NL